HMGB1 in Hormone-Related Cancer: A Potential Therapeutic Target

Hormones and Cancer

Volumn 5, Issue 3, 2014, Pages 127-139

  Srinivasan, Madhuwanti ^a   Banerjee, Souresh ^a   Palmer, Allison ^a   Zheng, Guoxing ^a   Chen, Aoshuang ^a   Bosland, Maarten C ^b   Kajdacsy Balla, André ^b   Kalyanasundaram, Ramaswamy ^a   Munirathinam, Gnanasekar ^a,b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BECLIN 1; CISPLATIN; CYTOKINE; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; ESTROGEN RECEPTOR; ETHYLPYRUVIC ACID; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; HOX PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; LENTIVIRUS VECTOR; METHOTREXATE; MYC PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; OXALIPLATIN; PROGESTERONE RECEPTOR; PROTEIN INHIBITOR; PROTEIN P53; PYRUVIC ACID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; BREAST DEVELOPMENT; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLORECTAL CANCER; DNA BINDING; DNA RECOMBINATION; DRUG TARGETING; EARLY DIAGNOSIS; ENDOCRINE FUNCTION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESTROGEN RESPONSIVE ELEMENT; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; KIDNEY CARCINOMA; LYMPHANGIOGENESIS; METASTASIS; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; THYROID CANCER; TRANSCRIPTION INITIATION; TUMOR INVASION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; FEMALE; MALE; NEOPLASMS; OVARIAN NEOPLASMS; PHYSIOLOGY; PROSTATIC NEOPLASMS; THYROID NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

ANIMALS; BREAST NEOPLASMS; FEMALE; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; MALE; NEOPLASMS; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; THYROID NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 84900393802     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-014-0175-0     Document Type: Review

References (120)

1. Walker JM, Goodwin GH, Johns EW, Wietzes P, Gaastra W (1977) A comparison of the amino-terminal sequences of two calf-thymus chromatin non-histone proteins. Int J Pept Protein Res 9: 220-223.
2. Muller S, Bianchi ME, Knapp S (2001) Thermodynamics of HMGB1 interaction with duplex DNA. Biochemistry 40: 10254-10261.
3. Strichman-Almashanu LZ, Bustin M, Landsman D (2003) Retroposed copies of the HMG genes: a window to genome dynamics. Genome Res 13: 800-812.
4. Agresti A, Scaffidi P, Riva A, Caiolfa VR, Bianchi ME (2005) GR and HMGB1 interact only within chromatin and influence each other's residence time. Mol Cell 18: 109-121.
5. Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani L, Bianchi ME, Taraseviciene L, Nordeen SK, Allegretto EA, Edwards DP (1998) High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol 18: 4471-4487.
6. Zappavigna V, Falciola L, Helmer-Citterich M, Mavilio F, Bianchi ME (1996) HMG1 interacts with HOX proteins and enhances their DNA binding and transcriptional activation. EMBO J 15: 4981-4991.
7. Stros M, Ozaki T, Bacikova A, Kageyama H, Nakagawara A (2002) HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 277: 7157-7164.
8. Agresti A, Lupo R, Bianchi ME, Muller S (2003) HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun 302: 421-426.
9. J. Liu, Y. Liu, H. Zhang, G. Chen, K. Wang, X. Xiao. KLF4 promotes the expression, translocation, and release of HMGB1 in RAW264. 7 macrophages in response to LPS, Shock 30 (2008) 260-266.
10. Davalos AR, Kawahara M, Malhotra GK, Schaum N, Huang J, Ved U, Beausejour CM, Coppe JP, Rodier F, Campisi J (2013) p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes. J Cell Biol 201: 613-629.
11. Rothermund K, Rogulski K, Fernandes E, Whiting A, Sedivy J, Pu L, Prochownik EV (2005) C-Myc-independent restoration of multiple phenotypes by two C-Myc target genes with overlapping functions. Cancer Res 65: 2097-2107.
12. Hoppe G, Talcott KE, Bhattacharya SK, Crabb JW, Sears JE (2006) Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1. Exp Cell Res 312: 3526-3538.
13. Ulloa L, Messmer D (2006) High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17: 189-201.
14. Erlandsson Harris H, Andersson U (2004) Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 34: 1503-1512.
15. Muller S, Ronfani L, Bianchi ME (2004) Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 255: 332-343.
16. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P (2005) HMGB1: guiding immunity from within. Trends Immunol 26: 381-387.
17. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004.
18. Todorova J, Pasheva E (2012) High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues. Oncol Lett 3: 214-218.
19. L. Padilla, S. Dakhel, J. L. Hernandez, S100 to receptor for advanced glycation end-products binding assay: Looking for inhibitors, Biochem Biophys Res Commun (2014).
20. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50: 2792-2808.
21. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A, Abraham E (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290: C917-C924.
22. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J, Musco G, Sitia G, Yap GS, Wan Y, Biron CA, Bianchi ME, Wang H, Chu WM (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110: 1970-1981.
23. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H (2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26: 174-179.
24. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A (2008) HMGB1: endogenous danger signaling. Mol Med 14: 476-484.
25. Parkkinen J, Raulo E, Merenmies J, Nolo R, Kajander EO, Baumann M, Rauvala H (1993) Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 268: 19726-19738.
26. Guo ZS, Liu Z, Bartlett DL, Tang D, Lotze MT (2013) Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res 3: 1-20.
27. Li G, Liang X, Lotze MT (2013) HMGB1: the central cytokine for all lymphoid cells. Front Immunol 4: 68.
28. Wang H, Yang H, Tracey KJ (2004) Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255: 320-331.
29. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, Billiar TR (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201: 1135-1143.
30. Andersson U, Tracey KJ (2004) HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum Dis Clin North Am 30: 627-637, xi.
31. Tang D, Kang R, Cao L, Zhang G, Yu Y, Xiao W, Wang H, Xiao X (2008) A pilot study to detect high mobility group box 1 and heat shock protein 72 in cerebrospinal fluid of pediatric patients with meningitis. Crit Care Med 36: 291-295.
32. Fang P, Schachner M, Shen YQ (2012) HMGB1 in development and diseases of the central nervous system. Mol Neurobiol 45: 499-506.
33. Lotze MT, DeMarco RA (2003) Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs 4: 1405-1409.
34. Tang D, Kang R, Zeh HJ 3rd, Lotze MT (2010) High-mobility group box 1 and cancer. Biochim Biophys Acta 1799: 131-140.
35. Oblak A, Jerala R (2011) Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol 2011: 609579.
36. Mittal D, Saccheri F, Venereau E, Pusterla T, Bianchi ME, Rescigno M (2010) TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 29: 2242-2252.
37. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360.
38. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28: 367-388.
39. Kang R, Tang D, Schapiro NE, Loux T, Livesey KM, Billiar TR, Wang H, van Houten B, Lotze MT, Zeh HJ (2014) The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene 33: 567-577.
40. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
41. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS, Paik YK, Kim HO (2003) Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 63: 2188-2193.
42. Livesey KM, Kang R, Zeh HJ 3rd, Lotze MT, Tang D (2012) Direct molecular interactions between HMGB1 and TP53 in colorectal cancer. Autophagy 8: 846-848.
43. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H (2005) Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 64: 92-100.
44. Gnanasekar M, Kalyanasundaram R, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A (2013) HMGB1: a promising therapeutic target for prostate cancer. Prostate Cancer 2013: 157103.
45. Sheng X, Du X, Zhang X, Li D, Lu C, Li Q, Ma Z, Song Q, Wang C (2009) Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat Med J 50: 455-464.
46. Liu F, Zhang Y, Peng Z, Gao H, Xu L, Chen M (2012) High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med 10: 135.
47. Liu PL, Tsai JR, Hwang JJ, Chou SH, Cheng YJ, Lin FY, Chen YL, Hung CY, Chen WC, Chen YH, Chong IW (2010) High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol 43: 530-538.
48. Q. Hao, X. Q. Du, X. Fu, J. Tian. Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi 30 (2008) 292-295.
49. Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R, Fujii K, Ohmori H, Kuniyasu H (2013) High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer 49: 741-751.
50. Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L, Tang D (2012) HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 72: 230-238.
51. Tang D, Loze MT, Zeh HJ, Kang R (2010) The redox protein HMGB1 regulates cell death and survival in cancer treatment. Autophagy 6: 1181-1183.
52. Chuangui C, Peng T, Zhentao Y (2012) The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Pathol Oncol Res 18: 1021-1027.
53. Abdul-Razzak KK, Garg L, Wen L, Reeck GR (1987) Fetal and newborn calf thymus as a source of chromatin proteins: purification of HMG-1 and HMG-2. Prep Biochem 17: 51-61.
54. Kimura K, Katoh N, Sakurada K, Kubo S (1985) Phosphorylation of high mobility group 1 protein by phospholipid-sensitive Ca2+-dependent protein kinase from pig testis. Biochem J 227: 271-276.
55. Nano R, Racanicchi L, Melzi R, Mercalli A, Maffi P, Sordi V, Ling Z, Scavini M, Korsgren O, Celona B, Secchi A, Piemonti L (2012) Human pancreatic islet preparations release HMGB1: (Ir)relevance for graft engraftment, cell transplant.
56. Lee KL, Pentecost BT, D'Anna JA, Tobey RA, Gurley LR, Dixon GH (1987) Characterization of cDNA sequences corresponding to three distinct HMG-1 mRNA species in line CHO Chinese hamster cells and cell cycle expression of the HMG-1 gene. Nucleic Acids Res 15: 5051-5068.
57. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R (2003) Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 10: 1863-1868.
58. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, Zornig M (2003) HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 17: 1295-1297.
59. Wu H, Ma J, Wang P, Corpuz TM, Panchapakesan U, Wyburn KR, Chadban SJ (2010) HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 21: 1878-1890.
60. Enokido Y, Yoshitake A, Ito H, Okazawa H (2008) Age-dependent change of HMGB1 and DNA double-strand break accumulation in mouse brain. Biochem Biophys Res Commun 376: 128-133.
61. Zetterstrom CK, Strand ML, Soder O (2006) The high mobility group box chromosomal protein 1 is expressed in the human and rat testis where it may function as an antibacterial factor. Hum Reprod 21: 2801-2809.
62. Chiva M, Mezquita C (1983) Quantitative changes of high mobility group non-histone chromosomal proteins HMG1 and HMG2 during rooster spermatogenesis. FEBS Lett 162: 324-328.
63. Liu Y, Yuan Y, Li Y, Zhang J, Xiao G, Vodovotz Y, Billiar TR, Wilson MA, Fan J (2009) Interacting neuroendocrine and innate and acquired immune pathways regulate neutrophil mobilization from bone marrow following hemorrhagic shock. J Immunol 182: 572-580.
64. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ (1999) Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126: 389-392.
65. Das D, Peterson RC, Scovell WM (2004) High mobility group B proteins facilitate strong estrogen receptor binding to classical and half-site estrogen response elements and relax binding selectivity. Mol Endocrinol 18: 2616-2632.
66. Onate SA, Prendergast P, Wagner JP, Nissen M, Reeves R, Pettijohn DE, Edwards DP (1994) The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences. Mol Cell Biol 14: 3376-3391.
67. Prendergast P, Onate SA, Christensen K, Edwards DP (1994) Nuclear accessory factors enhance the binding of progesterone receptor to specific target DNA. J Steroid Biochem Mol Biol 48: 1-13.
68. Zicari A, Centonze C, Realacci M, Buchetti B, Pietropolli A, Ticconi C (2008) Estradiol 17-beta and progesterone modulate inducible nitric oxide synthase and high mobility group box 1 expression in human endometrium. Reprod Sci 15: 559-566.
69. Verrijdt G, Haelens A, Schoenmakers E, Rombauts W, Claessens F (2002) Comparative analysis of the influence of the high-mobility group box 1 protein on DNA binding and transcriptional activation by the androgen, glucocorticoid, progesterone and mineralocorticoid receptors. Biochem J 361: 97-103.
70. Sparatore B, Patrone M, Passalacqua M, Pedrazzi M, Ledda S, Pontremoli S, Melloni E (2005) Activation of A431 human carcinoma cell motility by extracellular high-mobility group box 1 protein and epidermal growth factor stimuli. Biochem J 389: 215-221.
71. Pisetsky DS, Erlandsson-Harris H, Andersson U (2008) High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 10: 209.
72. Lee SM, Choi SE, Lee JH, Lee JJ, Jung IR, Lee SJ, Lee KW, Kang Y (2011) Involvement of the TLR4 (Toll-like receptor4) signaling pathway in palmitate-induced INS-1 beta cell death. Mol Cell Biochem 354: 207-217.
73. Zhu Y, Shu T, Lin Y, Wang H, Yang J, Shi Y, Han X (2011) Inhibition of the receptor for advanced glycation endproducts (RAGE) protects pancreatic beta-cells. Biochem Biophys Res Commun 404: 159-165.
74. Li M, Song L, Gao X, Chang W, Qin X (2012) Toll-like receptor 4 on islet beta cells senses expression changes in high-mobility group box 1 and contributes to the initiation of type 1 diabetes. Exp Mol Med 44: 260-267.
75. Ramasamy R, Yan SF, Schmidt AM (2011) Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 1243: 88-102.
76. Lee BW, Chae HY, Kwon SJ, Park SY, Ihm J, Ihm SH (2010) RAGE ligands induce apoptotic cell death of pancreatic beta-cells via oxidative stress. Int J Mol Med 26: 813-818.
77. Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R (2013) Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. Eur J Clin Invest 43: 286-291.
78. Lum HK, Lee KL (2001) The human HMGB1 promoter is modulated by a silencer and an enhancer-containing intron. Biochim Biophys Acta 1520: 79-84.
79. Chen J, Xi B, Zhao Y, Yu Y, Zhang J, Wang C (2012) High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer. Gynecol Oncol 126: 109-117.
80. Chen J, Liu X, Zhang J, Zhao Y (2012) Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference. J Cell Physiol 227: 3629-3638.
81. Zhang Y, Cheng Y, Ren X, Zhang L, Yap KL, Wu H, Patel R, Liu D, Qin ZH, Shih IM, Yang JM (2012) NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response. Oncogene 31: 1055-1064.
82. He Y, Zha J, Wang Y, Liu W, Yang X, Yu P (2013) Tissue damage-associated "danger signals" influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer Res 73: 629-639.
83. Gnanasekar M, Thirugnanam S, Ramaswamy K (2009) Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 34: 425-431.
84. Shetty AV, Thirugnanam S, Dakshinamoorthy G, Samykutty A, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A, Gnanasekar M (2011) 18alpha-glycyrrhetinic acid targets prostate cancer cells by down-regulating inflammation-related genes. Int J Oncol 39: 635-640.
85. D. X. Song, A. M. Chen, F. J. Guo, H. Liao, B. Z. Xie, B. Zhu, C. Chen. Differential proteomic analysis and function study of human prostate carcinoma cells with different osseous metastatic tendency. Zhonghua Yi Xue Za Zhi 88 (2008) 1197-1201.
86. Xiang YY, Wang DY, Tanaka M, Suzuki M, Kiyokawa E, Igarashi H, Naito Y, Shen Q, Sugimura H (1997) Expression of high-mobility group-1 mRNA in human gastrointestinal adenocarcinoma and corresponding non-cancerous mucosa. Int J Cancer 74: 1-6.
87. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170.
88. Radin JN, Gonzalez-Rivera C, Ivie SE, McClain MS, Cover TL (2011) Helicobacter pylori VacA induces programmed necrosis in gastric epithelial cells. Infect Immun 79: 2535-2543.
89. Akaike H, Kono K, Sugai H, Takahashi A, Mimura K, Kawaguchi Y, Fujii H (2007) Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 27: 449-457.
90. Bao G, Qiao Q, Zhao H, He X (2010) Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol 8: 52.
91. Zhang J, Zhu JS, Zhou Z, Chen WX, Chen NW (2012) Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo. Oncol Rep 27: 1511-1519.
92. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, Lim JB (2009) Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 7: 38.
93. B. Song, W. G. Song, Z. J. Li, Z. F. Xu, X. W. Wang, C. X. Wang, J. Liu, Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells, Cell Biochem Funct (2011).
94. Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, Sleeman JP (2001) Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 61: 1569-1577.
95. Chung HW, Lim JB, Jang S, Lee KJ, Park KH, Song SY (2012) Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci 103: 1714-1721.
96. Kang R, Loux T, Tang D, Schapiro NE, Vernon P, Livesey KM, Krasinskas A, Lotze MT, Zeh HJ 3rd (2012) The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A 109: 7031-7036.
97. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, Zeh HJ, Lotze MT (2010) HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29: 5299-5310.
98. Lin L, Zhong K, Sun Z, Wu G, Ding G (2012) Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol 138: 11-22.
99. Comprehensive molecular characterization of clear cell renal cell carcinoma, Nature 499 (2013) 43-49.
100. Birkhauser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J (2013) Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J Immunother 36: 102-111.
101. Fishman M, Seigne J (2002) Immunotherapy of metastatic renal cell cancer. Cancer Control 9: 293-304.
102. Liang X, De Vera ME, Buchser WJ, Romo de Vivar A, Chavez P, Loughran D et al (2012) Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res 72: 2791-2801.
103. Lotze MT, Buchser WJ, Liang X (2012) Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity. Autophagy 8: 1264-1266.
104. Mardente S, Mari E, Consorti F, Di Gioia C, Negri R, Etna M, Zicari A, Antonaci A (2012) HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. Oncol Rep 28: 2285-2289.
105. Mardente S, Zicari A, Consorti F, Mari E, Di Vito M, Leopizzi M, Della Rocca C, Antonaci A (2010) Cross-talk between NO and HMGB1 in lymphocytic thyroiditis and papillary thyroid cancer. Oncol Rep 24: 1455-1461.
106. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, Pass HI, Gaudino G, Carbone M, Yang H (2012) Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 72: 3290-3301.
107. Ohmori H, Luo Y, Fujii K, Sasahira T, Shimomoto T, Denda A, Kuniyasu H (2010) Dietary linoleic acid and glucose enhances azoxymethane-induced colon cancer and metastases via the expression of high-mobility group box 1. Pathobiology 77: 210-217.
108. Smolarczyk R, Cichon T, Matuszczak S, Mitrus I, Lesiak M, Kobusinska M, Kamysz W, Jarosz M, Sieron A, Szala S (2012) The role of glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. Arch Immunol Ther Exp (Warsz) 60: 391-399.
109. Liang X, Chavez AR, Schapiro NE, Loughran P, Thorne SH, Amoscato AA, Zeh HJ, Beer-Stolz D, Lotze MT, de Vera ME (2009) Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol 86: 599-607.
110. Ohnishi M, Katsuki H, Fukutomi C, Takahashi M, Motomura M, Fukunaga M, Matsuoka Y, Isohama Y, Izumi Y, Kume T, Inoue A, Akaike A (2011) HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats. Neuropharmacology 61: 975-980.
111. Saiwichai T, Sangalangkarn V, Kawahara K, Oyama Y, Chaichalotornkul S, Narkpinit S, Harnyuttanakorn P, Singhasivanon P, Maruyama I, Tancharoen S (2010) Green tea extract supplement inhibition of HMGB1 release in rats exposed to cigarette smoke. Southeast Asian J Trop Med Public Health 41: 250-258.
112. Li W, Ashok M, Li J, Yang H, Sama AE, Wang H (2007) A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One 2: e1153.
113. Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, Agresti A, Trisciuoglio L, Musco G, Bianchi ME (2007) Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 14: 431-441.
114. Girard JP (2007) A direct inhibitor of HMGB1 cytokine. Chem Biol 14: 345-347.
115. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, Tracey KJ (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 99: 12351-12356.
116. Dave SH, Tilstra JS, Matsuoka K, Li F, DeMarco RA, Beer-Stolz D, Sepulveda AR, Fink MP, Lotze MT, Plevy SE (2009) Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 86: 633-643.
117. Singh BN, Shankar S, Srivastava RK (2011) Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82: 1807-1821.
118. Chen D, Wan SB, Yang H, Yuan J, Chan TH, Dou QP (2011) EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem 53: 155-177.
119. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101: 296-301.
120. Faham A, Bennett D, Altin JG (2009) Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent Ag-specific and anti-tumour immunity. Vaccine 27: 5846-5854.